Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". Tsochatzis EA, Srivastava A, Rosenberg W. J Hepatol 2021;74:248-249.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tsochatzis EA, Srivastava A, Rosenberg W. Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". J Hepatol 2021;74:248-249.
PMID: 32981752